Structural

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Patient Reported Outcomes in National Registries: Why and How?

My Perspective on (Still) Unmet Needs in TAVR

Aortic Valve Replacement Versus Clinical Surveillance in Moderate Aortic Stenosis With Reduced Ejection Fraction: Meta-Analysis of Reconstructed Time-to-Event Data

Clinical Outcomes According to Aortic Stenosis Management: Insights From Real-World Practice

Debate: Echo-CT-Flouro Fusion is an Integral Tool for SHD Procedures (CON)

Debate: Echo-CT-Flouro Fusion is an Integral Tool for SHD Procedures (PRO)

TAVR-in-TAVR: Ready for Primetime?

The Worst is Yet to Come! A Predictive Model for Failed Aortic Bioprostheses

Understanding the Genetics and Classification of Connective Tissue Syndromes

Arial View of Antithrombotic Therapy Post TAVR

We Need More Data: Current and Future Research Directions

There Is Growing Evidence to Support Earlier AS Treatment: Guidelines and Clinical Practice Are Lagging Behind!

What Data and Valve Design Means for Valve Selection in Women

What would a patient consider a good outcome of intervention for symptomatic severe aortic stenosis

In younger patients receiving TAVR: why does the first intervention matter?

FX+: The Next Step in Addressing Lifetime Management

Where Do We Go Next?

Halt is Not Relevant

Halt is Relevant

Debate Con: Echo First and Only to Diagnose Bioprosthetic Valve Dysfunction /Failure

Debate Pro: Invasive Assessment is Mandatory to Confirm Bioprosthetic Valve Dysfunction /Failure

Severe PPM and High Residual Gradient Are Frequent and Negatively Impact Outcomes Following TAVR (PRO)

Severe PPM and High Residual Gradient Are Frequent and Negatively Impact Outcomes Following TAVR (PRO)

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

SAVR Will Have a Longer Lasting Durability Than TAVR

TAVR Will Have a Longer Lasting Durability Than SAVR

Medical, Surgical, and Transcatheter Treatment of Chronic Aortic Regurgitation

Subclinical Leaflet Thrombosis : Identification, Incidence and Importance

Definitions of Bioprosthetic Valve Dysfunction and Failure: Is There a Common Definition?

Role of Exercise Testing in Assessment of AR

Aortic Valve Replacement in BAV: Biprosthesis for Everyone? When to Consider TAVR? Do We Need Thoughtful RCTs?

Expanding Beyond Isolated RAVR – Widening the Offering in Complex Scenarios

RAVR or TAVR as a Cardiac Surgeon – My Program’s Growth and Alternatives

RAVR or TAVR as an Interventional Cardiologist – My Clinical Decision Making

Is Robotic Aortic Valve Replacement (RAVR) an Alternative to TAVR? Technique and Multicenter Experience

Management of Aortic Stenosis in Low-Risk Patients – Current Options and Controversies

SAVR is Clearly the Gold Standard in AS Patients Under 65 Years Old

TAVR in Young Patients - Current Treatment Patterns in the US

Introduction to the Redo TAVR App: Comprehensive Diagnosis and Procedure Planning

Hemodynamic Assessments After TAVR: Implications in Small Annulus Patients

The Cardiac Damage Paradigm to Finetune theTiming of Aortic Valve Replacement

Asymptomatic Severe AS – A Clinician’s Perspective

The Clinical Impact of Moderate AS

Updates on Randomized Trials in Moderate AS

Case Presentation of a Patient with a Small Annulus

Defining the Small Annulus Patient: TAVR and SAVR Perspectives

SMART Trial: Supra-Annular Self-Expanding Valves

My First Choice Would Be Balloon Expandable Valves!

Case Resolution of a Patient with a Small Annulus

Options for a Lifetime and Long-Term Durability

Moderate AS: Diagnosis, Risk Stratification, Current Management, and Ongoing Trials

Requirements for GDMT in UPSTREAM AVR Clinical Trials in (1) Preserved EF or (2) Reduced EF Patients

Case Presentation: Aortic Stenosis and Dyspnea – What Do We Call It? Is It HFpEF OR Is It the Valve?

Overview of Clinical Data on TAVR in Bicuspid AS - What's Needed?

Current Status of Dedicated Valve Platforms for Pure Aortic Regurgitation and Update on Trial Data

Why is TAVR Needed for Chronic Severe AR: Contemporary Insights

What's Needed to "Modernize" the Guidelines for Chronic Severe Aortic Regurgitation?

Case Discussion: Pre-emptive TAVR in Moderate AS “At-Risk” Patients